Literature DB >> 18022869

Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease.

John N Gordon1, Karen M Pickard, Antonio Di Sabatino, Joanna D Prothero, Sylvia L F Pender, Patrick M Goggin, Thomas T MacDonald.   

Abstract

BACKGROUND: In both ulcerative colitis (UC) and Crohn's disease (CD) there is a marked increase in mucosal IgG plasma cells (PC), although their precise role is not well established. In this study we isolated gut PCs from patients with IBD and normal controls and analyzed cytokine production, matrix metalloproteinase (MMP)-3 and tissue inhibitor of metalloproteinase (TIMP)-1 production, and PC longevity ex vivo.
METHODS: Lamina propria mononuclear cells (LPMCs) were isolated from patients with CD (n = 19), UC (n = 27), and normal controls (n = 42). PCs were further selected by immunomagnetic isolation using CD138 microbeads. Cytokine, MMP-3, and TIMP-1 expression was investigated by Taqman polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), Western blotting, and confocal microscopy. PC lifespan in vitro was studied by ELISpot analysis.
RESULTS: PCs from both controls and IBD patients contained high levels of transcripts for TGFbeta, whereas they did not contain significant transcripts for IL-4, IL-5, IL-10, IFNgamma, TNF, or IL-12p40. PCs from patients with CD and UC expressed significantly higher levels of MMP-3 protein and transcripts than controls (P < 0.0001). The vast majority of MMP-3-expressing PCs were IgG+ve. In culture, IgA PCs from both IBD patients and controls persisted for only a few days, but IgG PCs from IBD patients persisted for at least 3 weeks.
CONCLUSIONS: We have demonstrated that IgG PCs from patients with IBD express large amounts of MMP-3 and that they appear to be long-lived. These results identify a new pathway by which IgG PCs may damage the gut.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18022869     DOI: 10.1002/ibd.20302

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  18 in total

Review 1.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function.

Authors:  Reena Rani; Alan G Smulian; David R Greaves; Simon P Hogan; De'Broski R Herbert
Journal:  Eur J Immunol       Date:  2011-05-27       Impact factor: 5.532

3.  Dysregulated miR-34a-SIRT1-acetyl p65 axis is a potential mediator of immune activation in the colon during chronic simian immunodeficiency virus infection of rhesus macaques.

Authors:  Mahesh Mohan; Vinay Kumar; Andrew A Lackner; Xavier Alvarez
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

4.  The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis.

Authors:  Gábor Lakatos; Ferenc Sipos; Pál Miheller; István Hritz; Mária Zsófia Varga; Márk Juhász; Béla Molnár; Zsolt Tulassay; László Herszényi
Journal:  Pathol Oncol Res       Date:  2011-06-16       Impact factor: 3.201

Review 5.  Old and New Lymphocyte Players in Inflammatory Bowel Disease.

Authors:  Paolo Giuffrida; Gino Roberto Corazza; Antonio Di Sabatino
Journal:  Dig Dis Sci       Date:  2017-12-23       Impact factor: 3.199

6.  Protein kinase D1 mediates synergistic MMP-3 expression induced by TNF-α and bradykinin in human colonic myofibroblasts.

Authors:  James Yoo; Citlali Ekaterina Rodriguez Perez; Wenxian Nie; James Sinnett-Smith; Enrique Rozengurt
Journal:  Biochem Biophys Res Commun       Date:  2011-08-16       Impact factor: 3.575

7.  Mucosal changes induced by ischemia-reperfusion injury in a jejunal loop transplanted in oropharynx.

Authors:  Antonio Di Sabatino; Laura Brunetti; Paolo Biancheri; Rachele Ciccocioppo; Marco Guerci; Claudia Casella; Francesca Vidali; Thomas T MacDonald; Marco Benazzo; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-05-08       Impact factor: 3.397

Review 8.  Is there new hope for therapeutic matrix metalloproteinase inhibition?

Authors:  Roosmarijn E Vandenbroucke; Claude Libert
Journal:  Nat Rev Drug Discov       Date:  2014-11-07       Impact factor: 84.694

9.  Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17.

Authors:  Melba Muñoz; Markus M Heimesaat; Kerstin Danker; Daniela Struck; Uwe Lohmann; Rita Plickert; Stefan Bereswill; André Fischer; Ildikò Rita Dunay; Kerstin Wolk; Christoph Loddenkemper; Hans-Willi Krell; Claude Libert; Leif R Lund; Oliver Frey; Christoph Hölscher; Yoichiro Iwakura; Nico Ghilardi; Wenjun Ouyang; Thomas Kamradt; Robert Sabat; Oliver Liesenfeld
Journal:  J Exp Med       Date:  2009-12-07       Impact factor: 14.307

10.  Matrix metalloproteinases in the restorative proctocolectomy pouch of pediatric ulcerative colitis.

Authors:  Laura Mäkitalo; Maija Piekkala; Merja Ashorn; Mikko Pakarinen; Antti Koivusalo; Riitta Karikoski; Johanna Natunen; Ulpu Saarialho-Kere; Risto Rintala; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.